Alpha 2.0
Login Register
» Articles » PMID: 1386590

In Vitro Activity of Clarithromycin and Its 14-hydroxy-metabolite Against 203 Strains of Haemophilus Influenzae

Overview
Journal Infection
Date 1992 May 1
PMID 1386590
Citations 5
Authors
M G Bergeron
M Bernier
J Lecuyer
Affiliations
Soon will be listed here.
Abstract

The in vitro activity of clarithromycin alone and in combination with its primary human metabolite, 14-hydroxy-clarithromycin, was determined against 203 strains of Haemophilus influenzae. Microdilution broth MICs and MBCs of both clarithromycin and 14-hydroxy-clarithromycin were determined. The clarithromycin MIC50 was 4 mg/l and the MIC90 was 8 mg/l. The hydroxy metabolite was 2-4-fold more active with an MIC50 and MIC90 of 2 mg/l. The MBCs were equal to the MICs. The microbicidal effect of combinations of clarithromycin and 14-hydroxy-clarithromycin was tested using a microdilution checkerboard technique and the fractional inhibitory index was calculated. The combination was additive in 92% and synergistic in 8% of all strains of H. influenzae tested; no antagonism was found. The results were independent of the site of isolation of the strain or presence of beta-lactamase. These findings suggest the potential clinical utility of clarithromycin for the treatment of H. influenzae infections.

Citing Articles

In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections.

Davidson R Infect Drug Resist. 2019; 12:585-596.

PMID: 30881064 PMC: 6413744. DOI: 10.2147/IDR.S187226.

Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.

Aguilar L, Gimenez M, Costa J, Dal-Re R, Prieto J Antimicrob Agents Chemother. 1997; 41(5):927-30.

PMID: 9145846 PMC: 163827. DOI: 10.1128/AAC.41.5.927.

Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Aguilar L, Balcabao I, Salva P, Martin M, Costa J, Prieto J Antimicrob Agents Chemother. 1996; 40(1):17-21.

PMID: 8787872 PMC: 163049. DOI: 10.1128/AAC.40.1.17.

A comparative study of clarithromycin and amoxycillin suspensions in the treatment of pediatric patients with acute otitis media.

Coles S, Addlestone M, Kamdar M, Macklin J Infection. 1993; 21(4):272-8.

PMID: 8225637 DOI: 10.1007/BF01728911.

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Peters D, Clissold S Drugs. 1992; 44(1):117-64.

PMID: 1379907 DOI: 10.2165/00003495-199244010-00009.

References
1.
Hardy D, SWANSON R, Rode R, Marsh K, Shipkowitz N, Clement J . Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990; 34(7):1407-13. PMC: 175991. DOI: 10.1128/AAC.34.7.1407. View
2.
Kilian M . A taxonomic study of the genus Haemophilus, with the proposal of a new species. J Gen Microbiol. 1976; 93(1):9-62. DOI: 10.1099/00221287-93-1-9. View
3.
Hanson C, Bailer R, Gade E, Rode R, Fernandes P . Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). J Clin Microbiol. 1987; 25(6):1079-82. PMC: 269140. DOI: 10.1128/jcm.25.6.1079-1082.1987. View
4.
Fernandes P, Hardy D, Bailer R, McDonald E, Pintar J, Ramer N . Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. Antimicrob Agents Chemother. 1987; 31(8):1243-50. PMC: 174912. DOI: 10.1128/AAC.31.8.1243. View
5.
Kilian M . A rapid method for the differentiation of Haemophilus strains. The porphyrin test;. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974; 82(6):835-42. DOI: 10.1111/j.1699-0463.1974.tb02381.x. View